Sign in →

Epic Code LAB848 Ehrlichia/Anaplasma, Molecular Detection, PCR, Blood

Important Note

Order as Reference Miscellaneous #LAB848; indicate complete test name when ordering.

Additional Codes

Mayo Code: EHRL

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Useful For

Evaluating patients suspected of acute anaplasmosis or ehrlichiosis

Specimen Type

Whole Blood EDTA


Specimen Required


Container/Tube: Lavender top (EDTA)

Specimen Volume: 1 mL


Laboratory Test Directory Note:

COLLECTION NOTE: Volumes listed are in serum or plasma, draw approximately 2 1/2 times the requested volume in whole blood.

Specimen Minimum Volume

0.3 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Whole Blood EDTA Refrigerated 7 days

Reject Due To

Gross hemolysis OK
Gross lipemia Reject

Cautions

This assay should not be used for screening asymptomatic individuals, and should only be used to test patients with signs and symptoms of ehrlichiosis or anaplasmosis.

 

A negative result does not indicate absence of disease.

 

Inadequate specimen draw or improper conditions for storage or transport may invalidate test results.

 

This test may detect DNA of Ehrlichia canis (reported to cause asymptomatic infection in Venezuela only).

 

This PCR test does not detect DNA of Rickettsia (formerly Ehrlichia) sennetsu, which has been reported to cause a rare mononucleosis-like illness in humans (in Japan and Malaysia).

Clinical Information

Ehrlichiosis and anaplasmosis are a group of emerging zoonotic tick-borne infections caused by Ehrlichia and Anaplasma species, respectively. These obligate intracellular, gram-negative rickettsial organisms infect leukocytes and cause a potentially serious febrile illness in humans.

 

Human granulocytic anaplasmosis (HA) is caused by Anaplasma phagocytophilum, which is transmitted through the bite of an infected Ixodes species tick. The epidemiology of this infection in the United States is very much like that of Lyme disease (caused by Borrelia burgdorferi) and babesiosis (caused primarily by Babesia microti), which all have the same tick vector. HA is most prevalent in the upper Midwest and in other areas of the United States that are endemic for Lyme disease.

 

Human monocytic ehrlichiosis (HE) is caused by Ehrlichia chaffeensis, which is transmitted by the Lone Star tick, Amblyomma americanum. Most cases of HE have been reported from the southeastern and south-central regions of the United States. E ewingii, the known cause of canine granulocytic ehrlichiosis, can occasionally cause an HE-like illness in humans. Clinical features and laboratory abnormalities are similar to those of E chaffeensis infection, and antibodies to E ewingii cross-react with current serologic assays for detection of antibodies to E chaffeensis.

 

Most recently, Mayo Clinic Laboratories detected a new species of Ehrlichia in patients with exposure to ticks in Wisconsin and Minnesota. This organism is most closely related to E muris and has therefore been referred to as the E muris-like agent or EMLA. The name E muris eauclairensis has recently been proposed after the city in which the first case was described. E muris eauclairensis causes a similar disease to ehrlichiosis due to E chaffeensis and E ewingii, and may cause more severe disease in immunocompromised hosts.

 

Most cases of anaplasmosis and ehrlichiosis are subclinical or mild, but infection can be severe and life-threatening in some individuals. Fever, fatigue, malaise, headache, and other "flu-like" symptoms, including myalgias, arthralgias, and nausea, occur most commonly. Central nervous system involvement can result in seizures and coma.

 

Diagnosis may be difficult since the patient's clinical course is often mild and nonspecific. This symptom complex is easily confused with other illnesses such as influenza, or other tick-borne zoonoses such as Lyme disease, babesiosis, and Rocky Mountain spotted fever. Clues to the diagnosis of ehrlichiosis in an acutely febrile patient after tick exposure include laboratory findings of leukopenia or thrombocytopenia and elevated serum aminotransferase levels. However, while these abnormal laboratory findings are frequently seen, they are not specific. Rarely, intra-granulocytic or monocytic morulae may be observed on peripheral blood smear, but this is not a reliable means of diagnosing cases of human ehrlichiosis or anaplasmosis.

 

Definitive diagnosis is usually accomplished through PCR and serologic methods. Serologic testing is done primarily for confirmatory purposes, by demonstrating a 4-fold rise or fall in specific antibody titers to Ehrlichia species or Anaplasma antigens. There is not currently a commercially available specific serologic test for E muris eauclairensis, but cross-reactivity with the other Ehrlichia species by serology may be detected.

 

PCR techniques allow direct detection of pathogen-specific DNA from patients' whole blood and is the preferred method for detection during the acute phase of illness. The Mayo PCR assay is capable of detecting and differentiating A phagocytophilum, E chaffeensis, E ewingii, and E muris eauclairensis.

 

It is important to note that concurrent infection with A phagocytophilum, Borrelia burgdorferi, and Babesia microti is not uncommon as these organisms share the same Ixodes tick vector, and additional testing for these pathogens may be indicated.

Method Name

Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization

Report Available

Same day/1 to 4 days

Reporting Name

Ehrlichia/Anaplasma PCR, B

Reference Values

Negative

Interpretation

Positive results indicate presence of specific DNA from Ehrlichia chaffeensis, E ewingii, E muris eauclairensis organism, or Anaplasma phagocytophilum and support the diagnosis of ehrlichiosis or anaplasmosis.

 

Negative results indicate absence of detectable DNA from any of these 4 pathogens in specimens, but do not exclude the presence of these organisms or active or recent disease.

 

Since DNA of E ewingii is indistinguishable from that of E canis by this rapid PCR assay, a positive result for E ewingii/canis indicates the presence of DNA from either of these 2 organisms.

Method Description

Nucleic acid is extracted from the pathogens in blood using the automated MagNA Pure LC system. The extract is then transferred to a 96-well Lightcycler 480 dish for amplification. The LightCycler 480 is an automated instrument that amplifies and monitors the development of target nucleic acid (amplicon) after each cycle of PCR. The DNA target for PCR assay is groEL, the open reading frame gene segment of the heat-shock protein operon (groEL), which is present at a frequency of 1 copy per organism in pathogenic species of Anaplasma and Ehrlichia. A specific base pair DNA target sequence is amplified by PCR. The detection of amplicon is based on fluorescence resonance energy transfer (FRET), which utilizes a hybridization probe with a donor fluorophore, fluorescein, at the 3' end and a second hybridization probe with an acceptor fluorophore, LC-Red 640, at the 5' end. When the target amplicon is present, the LC-Red 640 emits a measurable and quantifiable light signal at a specific wavelength. Presence of the specific organism nucleic acid may be confirmed by performing a melting curve analysis of the amplicon. Using features of the melting curve analysis, the assay primers and specific hybridization probes are able to detect and differentiate among Anaplasma phagocytophilum, Ehrlichiosis chaffeensis, Ehrlichia muris eauclairensis, and Ehrlichia ewingii/canis. Due to close proximity of the melting curves of Ehrlichia ewingii and Ehrlichia canis, this assay cannot distinguish between these 2 organisms.(Cockerill FR, Uhl FR: Applications and challenges of real-time PCR for the clinical microbiology laboratory. In Rapid Cycle Real-Time PCR. Edited by U Reischl, C Wittwer, F Cockerill. Springer, NY, 2002)

Day(s) Performed

Monday through Saturday

Clinical Reference

1. Bakken JS, Dunler JS: Human granulocytic ehrlichiosis. Clin Infect Dis 2000 Aug;31(2):554-560

2. Dunler JS, Bakken JS: Human ehrlichioses: newly recognized infections transmitted by ticks. Ann Rev Med 1998;49:201-213

3. Krause PJ, McKay K, Thompson CA, et al: Disease-specific diagnosis of coinfecting tickborne zoonoses: babesiosis, human granulocytic ehrlichiosis, and Lyme disease. Clin Infect Dis 1999 May 1;34(9):1184-1191

4. McQuiston JH, Paddock CD, Holman RC, Childs JE: The human ehrlichioses in the United States. Emerging Infect Dis 1999 Sept-Oct;5(5):635-642

5. Pritt BS, Sloan LM, Johnson DK, et al: Emergence of a new pathogenic Ehrlichia species, Wisconsin and Minnesota, 2009. N Engl J Med 2011 Aug 4;365(5):422-429

6. Johnson DK, Schiffman E, Davis JP, et al. Human infection with Ehrlichia muris-like Pathogen, United States, 2007-2013. Emerging Infect Dis 2015; 21(10):1794-99

Test Classification

This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

87798 x 4

LOINC Code Information

Test ID Test Order Name Order LOINC Value
EHRL Ehrlichia/Anaplasma PCR, B 87548-4

 

Result ID Test Result Name Result LOINC Value
84319 Anaplasma phagocytophilum 87558-3
23663 Ehrlichia chaffeensis 87559-1
23664 Ehrlichia ewingii/canis 87560-9
32010 Ehrlichia muris eauclairensis 87561-7